- Home
- SKYE vs SILC Comparison
SKYE vs SILC Comparison
Compare SKYE & SILC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- SILC
- Stock Information
- Founded
- SKYE 2012
- SILC 1987
- Country
- SKYE United States
- SILC Israel
- Employees
- SKYE N/A
- SILC N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- SILC Computer Manufacturing
- Sector
- SKYE Health Care
- SILC Technology
- Exchange
- SKYE Nasdaq
- SILC Nasdaq
- Market Cap
- SKYE 80.7M
- SILC 84.7M
- IPO Year
- SKYE N/A
- SILC 1994
- Fundamental
- Price
- SKYE $1.81
- SILC $14.99
- Analyst Decision
- SKYE Buy
- SILC Hold
- Analyst Count
- SKYE 6
- SILC 2
- Target Price
- SKYE $16.60
- SILC N/A
- AVG Volume (30 Days)
- SKYE 1.7M
- SILC 16.7K
- Earning Date
- SKYE 05-08-2025
- SILC 04-28-2025
- Dividend Yield
- SKYE N/A
- SILC N/A
- EPS Growth
- SKYE N/A
- SILC N/A
- EPS
- SKYE N/A
- SILC N/A
- Revenue
- SKYE N/A
- SILC $58,134,000.00
- Revenue This Year
- SKYE N/A
- SILC $6.22
- Revenue Next Year
- SKYE N/A
- SILC $19.10
- P/E Ratio
- SKYE N/A
- SILC N/A
- Revenue Growth
- SKYE N/A
- SILC N/A
- 52 Week Low
- SKYE $1.14
- SILC $11.35
- 52 Week High
- SKYE $13.49
- SILC $18.24
- Technical
- Relative Strength Index (RSI)
- SKYE 48.48
- SILC 56.04
- Support Level
- SKYE $1.36
- SILC $14.50
- Resistance Level
- SKYE $2.30
- SILC $16.00
- Average True Range (ATR)
- SKYE 0.21
- SILC 0.72
- MACD
- SKYE 0.02
- SILC 0.20
- Stochastic Oscillator
- SKYE 42.35
- SILC 67.94
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters; Edge Networking Solutions; FPGA Based Cards; x86 Open Appliances Bypass Switches and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.